Combined Effects of Programmed Cell Death-1 Blockade and Endostar on Brain Metastases of Lung Cancer

被引：3

作者：

Qi, Xuejiao ^{[1
]}

Zhao, Yinlong ^{[2
]}

Yang, Song ^{[3
]}

Sun, YuMeng ^{[3
]}

Liu, Honglei ^{[4
]}

Liu, Pengyu ^{[3
]}

Feng, Shiyao ^{[3
]}

Tui, Hongbo ^{[3
]}

Yuan, Zheng ^{[3
]}

Yang, Jiankai ^{[1
,3
]}

Bu, Hui ^{[1
]}

机构：

[1] Hebei Med Univ, Hosp 2, Dept Neurol, Shijiazhuang 050000, Hebei, Peoples R China

[2] Hebei Med Univ, Hosp 2, Dept Intens Care Unit, Shijiazhuang 050000, Hebei, Peoples R China

[3] Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China

[4] Third Hosp Shijiazhuang, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2023年 / 23卷 / 06期

关键词：

Lung cancer; brain metastasis; immune checkpoint; PD-1; endostar; tumor metastasis; ANGIOGENESIS; CHECKPOINTS; INHIBITION; MECHANISMS; THERAPY; NSCLC;

D O I：

10.2174/1871520622666220827125929

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The blockade of programmed cell death-1 (PD-1) and recombinant human endostatin can be used for the treatment of non-small cell lung cancer (NSCLC) and its metastasis. This study aims to explore the therapeutically potential of PD-1 blockade plus Endostar in brain metastasis of NSCLC. Methods: The mouse brain metastases model was established using Lewis lung carcinoma luciferase (LLC-Luc) and PC-9-Luc cells. Tumor metastasis in the brain and tumor burden were analyzed by using bioluminescence imaging (BLI), qRT-PCR and ELISA which were used to determine the mRNA and protein levels of biomarkers in tumor tissues. Immunohistochemical staining was used to determine the expression and location of CD31 in tumor tissues in the brain. Results: Treatment with anti-PD-1 and Endostar suppressed tumor metastasis in the brain and prolonged overall survival rate in LLC-Luc and PC-9-Luc brain metastases mouse model. In addition, treatment with anti-PD-1 and Endostar inhibited the expressions of CD31 and VEGF in tumor tissues in the brain. Furthermore, treatment with anti-PD-1 and Endostar significantly suppressed the levels of IL1 beta, IFN gamma, and TGF beta in the tumor tissues. Conclusion: The combination of PD-1 blockade and endostar suppressed brain metastases of NSCLC.

引用

页码：709 / 716

页数：8

共 33 条

[1] Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review [J].

Arbour, Kathryn C. ;

Riely, Gregory J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (08) :764-774

[2] Anti-angiogenic therapies in brain metastases [J].

Berghoff A.S. ;

Preusser M. .

memo - Magazine of European Medical Oncology, 2018, 11 (1) :14-17

[3] Next generation immune-checkpoints for cancer therapy [J].

Donini, Chiara ;

D'Ambrosio, Lorenzo ;

Grignani, Giovanni ;

Aglietta, Massimo ;

Sangiolo, Dario .

JOURNAL OF THORACIC DISEASE, 2018, 10 :S1581-S1601

[4] IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using 'cracked' adenoproducer cells [J].

Esandi, MC ;

van Someren, GD ;

Bout, A ;

Mulder, AH ;

van Bekkum, DW ;

Valerio, D ;

Noteboom, JL .

GENE THERAPY, 1998, 5 (06) :778-788

[5] Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer [J].

Fang, Likui ;

Zhao, Wuchen ;

Ye, Bo ;

Chen, Da .

FRONTIERS IN ONCOLOGY, 2021, 11

[6] Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC) [J].

Hall, Richard D. ;

Le, Tri M. ;

Haggstrom, Daniel E. ;

Gentzler, Ryan D. .

TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) :515-523

[7] The biology and management of non-small cell lung cancer [J].

Herbst, Roy S. ;

Morgensztern, Daniel ;

Boshoff, Chris .

NATURE, 2018, 553 (7689) :446-454

[8] Tracking the Evolution of Non-Small-Cell Lung Cancer [J].

Jamal-Hanjani, M. ;

Wilson, G. A. ;

McGranahan, N. ;

Birkbak, N. J. ;

Watkins, T. B. K. ;

Veeriah, S. ;

Shafi, S. ;

Johnson, D. H. ;

Mitter, R. ;

Rosenthal, R. ;

Salm, M. ;

Horswell, S. ;

Escudero, M. ;

Matthews, N. ;

Rowan, A. ;

Chambers, T. ;

Moore, D. A. ;

Turajlic, S. ;

Xu, H. ;

Lee, S. -M. ;

Forster, M. D. ;

Ahmad, T. ;

Hiley, C. T. ;

Abbosh, C. ;

Falzon, M. ;

Borg, E. ;

Marafioti, T. ;

Lawrence, D. ;

Hayward, M. ;

Kolvekar, S. ;

Panagiotopoulos, N. ;

Janes, S. M. ;

Thakrar, R. ;

Ahmed, A. ;

Blackhall, F. ;

Summers, Y. ;

Shah, R. ;

Joseph, L. ;

Quinn, A. M. ;

Crosbie, P. A. ;

Naidu, B. ;

Middleton, G. ;

Langman, G. ;

Trotter, S. ;

Nicolson, M. ;

Remmen, H. ;

Kerr, K. ;

Chetty, M. ;

Gomersall, L. ;

Fennell, D. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (22) :2109-2121

[9] Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma [J].

Li, Yuan ;

Huang, Pan ;

Peng, Hongju ;

Yue, Hongcheng ;

Wu, Min ;

Liu, Shanshan ;

Qin, Rongsheng ;

Fan, Juan ;

Han, Yunwei .

CANCER MANAGEMENT AND RESEARCH, 2019, 11 :3469-3479

[10] Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells [J].

Ling, Yun ;

Yang, Yong ;

Lu, Na ;

You, Qi-Dong ;

Wang, Sen ;

Gao, Ying ;

Chen, Yan ;

Guo, Qing-Long .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 361 (01) :79-84

← 1 2 3 4 →